Preliminary Final Report

Key points

• Reported Revenue: $12,050,000 (Up 145%)
• Loss for the Period: $7,465,000 (Down 25%)
• No Dividends Paid or Declared
• Net Tangible Assets: $0.03 per share
• Genentech Upfront Payment: $8,340,000

Full summary

Starpharma Holdings Ltd announced its preliminary final report for the year ended 30 June 2026. The company reported a substantial increase in revenue to $12,050,000, up 145% from $4,912,000 in the prior year, largely due to an $8,340,000 upfront payment under the Collaboration and License Agreement with Genentech. The loss for the period attributable to members decreased by 25% to $7,465,000, reflecting increased revenue but also higher research and development expenditures. The company did not declare any dividends for the period. Net tangible assets per ordinary share declined to $0.03 from $0.05 in the previous year.